Australia markets open in 8 hours 35 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
53.42+3.00 (+5.95%)
At close: 04:00PM EDT
53.20 -0.22 (-0.41%)
After hours: 05:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close50.42
Bid53.47 x 3000
Ask54.00 x 1300
Day's range52.16 - 53.55
52-week range46.93 - 58.10
Avg. volume2,369,151
Market cap133.407B
Beta (5Y monthly)0.36
PE ratio (TTM)19.08
EPS (TTM)2.80
Earnings dateN/A
Forward dividend & yield1.75 (3.27%)
Ex-dividend date26 May 2022
1y target est70.75
  • Motley Fool

    Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA

    Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.

  • Motley Fool

    Why Sanofi May Be a Frontrunner in Endemic COVID-19

    Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.

  • Financial Times

    Sanofi-GSK Covid vaccine found effective against Omicron

    Sanofi and GlaxoSmithKline have reported promising results from trials of their Covid-19 vaccine, which has proved to be particularly effective against the Omicron strain of coronavirus. The vaccine targets the original and the Beta strains of coronavirus but was also tested against the more recent Omicron variant. When used as a first dose, it demonstrated a 64.7 per cent efficacy rate against symptomatic infection overall in adults, and was 72 per cent effective against infections caused by Omicron.